Ironwood Pharmaceuticals, Inc. (IRWD)

Market Cap	1.48B
Revenue (ttm)	427.28M
Net Income (ttm)	-917.29M
Shares Out	156.03M
EPS (ttm)	-6.04
PE Ratio	n/a
Forward PE	16.05
Dividend	n/a
Ex-Dividend Date	n/a

Volume	51,427
Open	9.35
Previous Close	9.43
Day's Range	9.34 - 9.52
52-Week Range	8.07 - 12.66
Beta	0.93
Analysts	Buy
Price Target	19.00 (+99.58%)
Earnings Date	Nov 2, 2023

About IRWD

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visc...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Feb 3, 2010
• Employees: 219
• Stock Exchange: NASDAQ
• Ticker Symbol: IRWD

Financial Performance

In 2022, IRWD's revenue was $410.60 million, a decrease of -0.76% compared to the previous year's $413.75 million. Earnings were $175.07 million, a decrease of -66.87%.

Analyst Forecast

According to one analyst, the rating for IRWD stock is "Buy" and the 12-month stock price forecast is $19.0.

Price Target

$19.0

(99.58% upside)

Analyst Consensus: Buy